Defining the prognosis of early stage chronic lymphocytic leukaemia patients.

摘要: Approximately 70% of chronic lymphocytic leukaemia (CLL) patients present with early stage disease, therefore defining which patients will progress and require treatment is a major clinical challenge. Here, we present the largest study prognostic markers ever carried out in Binet A patients (n = 1154) median follow-up 8 years. We assessed the prognostic impact lymphocyte doubling time (LDT), immunoglobulin gene (IGHV) mutation status, CD38 expression, ZAP-70 expression and fluorescence situ hybridization (FISH) cytogenetics regards to to first (TTFT) overall survival (OS). Univariate analysis revealed LDT as the most parameter for TTFT, IGHV status most OS. FISH were also variables; combinations these increased prognostic power concordant cases. Multivariate revealed that only LDT, IGHV age at diagnosis were independent prognostic variables TTFT Therefore, status and CD38 have independent value CLL and should be performed part routine diagnostic workup. ZAP-70 expression not stage disease can omitted but should be undertaken disease progression direct strategy.